Published date:
23/01/2023
Summary:
Mocravimod is the only S1PR modulator being developed to treat blood cancers and improve CAR-T therapy
Phase 1b/2a data has shown mocravimod is safe and well tolerated
Dublin, Ireland – January 23, 2023 – Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod today announced that the first patients have been enrolled in the pivotal MO-TRANS global Phase 2b/3 study evaluating mocravimod in AML patients undergoing allogeneic hematopoietic cell transplant (HCT).
